Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences Q3 net loss widens to $51.1 million; cash $700.5 million

Mixed Impact 3 of 5 earnings

Tyra Biosciences reported third quarter 2026 results with a net loss of $51.1 million, up from $29.9 million a year earlier, as research and development and general and administrative expenses rose. The company said it ended the quarter with $700.5 million in cash, cash equivalents and marketable securities, and that this, together with a $400 million financing completed in September 2026, funds planned operations through 2030.

Key points

  • Net loss was $51.1 million, or $0.74 per share, for the quarter ended September 30, 2026, compared with $29.9 million, or $0.50 per share, a year earlier.
  • R&D expenses rose to $43.1 million from $25.5 million, driven mainly by dabogratinib trials; G&A expenses rose to $11.7 million from $7.5 million.
  • Initial Phase 2 SURF302 results reported in September 2026 showed a 79% overall response rate at 60 mg QD among 14 participants with single and multiple marker lesions.
  • Cash, cash equivalents and marketable securities were $700.5 million as of September 30, 2026.

The filing

CompanyTyra Biosciences, Inc. (TYRA)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:03 AM ET
Accession number0001193125-26-454474

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:23 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.